ProCE Banner Activity

The SLIM LIVER: Effects of Semaglutide on Metabolic Dysfunction–Associated Steatotic Liver Disease in People Living With HIV

Conference Coverage
Slideset

In the SLIM LIVER study, low-dose semaglutide was associated with reductions in liver fat, BMI, and waist circumference in people living with HIV and MASLD receiving suppressive ART.

Released: March 07, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare